Aaron G. Baugh

Molecular Biologist • Tumor Immunology PhD candidate • Keck School of Medicine at USC @KECKSchool_USC @uscnorris • @RoussosTorres Lab

[Journal for ImmunoTherapy of Cancer @jitcancer]

We're pleased to share that JITC's 2025 Impact Factor increased to 11.7, reflecting the growing reach and citation of work published in the Journal. This metric is one of several indicators of the Journal's performance and engagement. Thank you to our authors, reviewers, editors, and readers for contributing to another strong year for JITC.

Interested in cutting-edge immunology research. Explore JITC: https://t.co/y4LPi8B8aY

[Aaron G. Baugh @AaronGBaugh]

@ivancalcantara I’ve done “oh I work in a lab” 😂

[bioRxiv Immunology @biorxiv_immuno]

A class act: HDAC1-Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells https://t.co/EAqnMjlH8X #biorxiv_immuno

[Aaron G. Baugh @AaronGBaugh]

Excited to share our pre-print in the @RoussosTorres lab with @adamlmaclean on the mechanism of #HDAC inhibition in #MDSC to decrease T cell suppression

A class act: HDAC1-Malat1 regulates MDSC apoptosis and cell cycling to decrease suppression of T cells https://t.co/AGMPY2jNI2

[Aaron G. Baugh @AaronGBaugh]

@ivancalcantara Oh my god they’re gorgeous

[Aaron G. Baugh @AaronGBaugh]

Check out our pre-print on using iterative logistic regression to identify marker genes and tease out cell state differences

[bioRxiv Bioinfo @biorxiv_bioinfo]

Inference of marker genes of subtle cell state changes via iterative logistic regression https://t.co/HlXLrc6FTc #biorxiv_bioinfo

[Aaron G. Baugh @AaronGBaugh]

Check out one of our latest pre-prints examining myeloid-T cell interactions and B cell activation in breast cancer immunotherapy!

[bioRxiv Cancer Bio @biorxiv_cancer]

Cancer systems immunology reveals myeloid - T cell interactions and B cell activation mediate response to checkpoint inhibition in ... https://t.co/wKA284nPZJ #biorxiv_cancer

[Aaron G. Baugh @AaronGBaugh]

@ivancalcantara Ahhhhh so happy for you!!

[Aaron G. Baugh @AaronGBaugh]

@ivancalcantara Congrats!!!!

[Aaron G. Baugh @AaronGBaugh]

@chamorrodf @PittGIM @tinahoyosv @johnmgonzalez @AndresFCardonaZ @ChristodoulouMD Congrats again!!! 🎉🎉

[Aaron G. Baugh @AaronGBaugh]

Excited to share our recent review in @ARNM_ASP on triple combination of radiotherapy, epigenetic modulation, and immunotherapy in ICI resistant triple negative breast cancer!

https://t.co/mXaKQJm5ag

#radiotherapy #epigenetics #immunotherapy #immunecheckpoint #TNBC

[Advances in Radiotherapy & Nuclear Medicine (ARNM) @ARNM_ASP]

📢Welcome to read the paper "Targeting EZH2 to mitigate immune checkpoint resistance in ARID1A-deficient triple-negative
breast cancer"
👥By Lauren Lukas, et al.
Read #article here: https://t.co/bCUWCAav43

[Aaron G. Baugh @AaronGBaugh]

@laurensomes Congrats!!! 🎉🎉

[Aaron G. Baugh @AaronGBaugh]

@ivancalcantara Hey feeding that one mouse is HARD, esp when they got attitudeee

[USC Norris Comprehensive Cancer Center @uscnorris]

Unlocking New Insights: The intersection of Social Determinants of Health and Tumor Immunosuppression. Breast cancer affects millions. Did you know that non-medical factors such as income, education, and access to healthcare can greatly affect breast cancer outcomes? Learn about pioneering research that is exploring how these factors influence the tumor microenvironment, with a particular focus on Hispanic and Latino communities.

[Aaron G. Baugh @AaronGBaugh]

@DNSidiropoulos @sitcancer @break_cancer You did great! 🙌🏻🙌🏻

[Aaron G. Baugh @AaronGBaugh]

Super excited to present the @RoussosTorres lab’s latest findings on #epigenetic alteration of #MDSC suppressive signaling within the #STAT3 axis in #breastcancer to improve combination #immunotherapy at #SITC24 (Abstract 874 in #JITC)

https://t.co/tGtKsuvBEd

[Tower Cancer Research Foundation @TowerCancer]

Imagine harnessing the power of our body’s own immune system to defeat breast cancer!
That’s the exciting goal of research Dr. Torres is now conducting, made possible by your support.
https://t.co/K9mYU2PTdm
#drsusanlovefund #dslf #towercancer #tcrf #bcam #breastcancerawareness

[Evanthia Roussos Torres, MD, PhD @RoussosTorres]

Thank you @AACR and @BCRFcure for supporting the work of my lab and amazing team science with @adamlmaclean lab! Inaugural #AACRGrant workshop sparked wonderful collaborations and networking!

[Aaron G. Baugh @AaronGBaugh]

@liv4bacteria No pls why 🙈🙃😢

[Aaron G. Baugh @AaronGBaugh]

Full article (Baugh et al., 2024) can be found below! Give it a read and see what new exciting breast cancer research we’re working on!

https://t.co/3eUVWDtYEi

[USC Norris Comprehensive Cancer Center @uscnorris]

Published in the Journal Clinical & Experimental Metastasis, Dr. Evanthia Roussos Torres, co-leader of the USC Norris Tumor Immunology and Microenvironment Program, and her team developed a new model using a specific breast cancer cell line. Besides investigating mechanisms of metastatic progression, this new model may be used for the rationalized development of novel therapeutic interventions and assessment of therapeutic responses, particularly those targeting HER2-positive cancers. Read the full publication here: https://t.co/jBYzFvEMyX.